Canaccord lowered the firm’s price target on Ventyx Biosciences to $16 from $20 and keeps a Buy rating on the shares. The firm noted the company will host its virtual Investor Day today to report top-line results from the Phase II trial for VTX2735 in CAPS and top-line results from the Phase I trial for VTX3232, a CNS penetrant NLRP3 inhibitor, in healthy volunteer. They also noted they raised $100M in a private placement further solidifying their balance sheet.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VTYX:
- Ventyx Biosciences to hold virtual investor event
- Ventyx Biosciences Secures $100M in Private Placement Deal
- Ventyx Biosciences to sell 11.17M shares at $8.95 in private placement
- Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
- SHAREHOLDER ALERT: Potential Recovery for Ventyx Biosciences, Inc. (VTYX) Investors
